| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T303 |
0-105 |
Sentence |
denotes |
CaNa2EDTA was approved by FDA in chelation therapy for lowering blood lead levels a long time ago (1953). |
| T304 |
106-239 |
Sentence |
denotes |
Then, different (commercially available) iron chelating agents, expected to work in chelating zinc ion as well, were approved by FDA. |
| T305 |
240-373 |
Sentence |
denotes |
Chelation therapy comprises intravenous or oral administration of chelating agents that remove metal ions such as zinc from the body. |
| T306 |
374-471 |
Sentence |
denotes |
Cells synthesising high amounts of ACE or ACE2 needs of high amounts of bioavailable (free) zinc. |
| T307 |
472-614 |
Sentence |
denotes |
Therefore, it is conceivable that plasma levels of free zinc may influence not only ACE and ACE2 activities but also their cellular synthesis. |
| T308 |
615-746 |
Sentence |
denotes |
Indeed, both ACE and ACE2 synthesis might be particularly sensitive to reduction of free zinc levels in case of their upregulation. |
| T309 |
747-939 |
Sentence |
denotes |
In addition, metal chelating agents, by limiting the availability of free zinc to cells, might have effects on both ACE2/ACE synthesis and conformation (when assembled on the plasma membrane). |
| T310 |
940-1237 |
Sentence |
denotes |
Indeed, the closed conformer of ACE2 homodimer that is the preferential conformation for virus binding [28], needs the presence of both zinc and substrate/inhibitor in the catalytic site [90], suggesting that zinc chelation (differently from MLN-4760) might also inhibit ACE2-mediated viral entry. |
